Toronto, Canada

Nigel Sharfe


Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Toronto, CA (2004 - 2007)
  • Ontario, CA (2009)

Company Filing History:


Years Active: 2004-2009

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Nigel Sharfe

Introduction

Nigel Sharfe is a notable inventor based in Toronto, Canada, recognized for his significant contributions to the field of biomedical research. With a total of four patents to his name, he has made strides in developing novel compounds and methods that have the potential to impact the treatment of various health conditions.

Latest Patents

Among his latest patents, Sharfe has developed compounds for modulating cell proliferation. These novel styrylacrylonitrile compounds are particularly useful in treating a variety of cell proliferative disorders, including cancer. Additionally, he has patented methods of modulation of the immune system. This involves the manipulation of the EphB6 receptor and its active Eph partners, which allows for the regulation of T cell responses, including TCR signaling, T cell proliferation, and the induction of T cell death. These methods of modulating EphB6 are described along with various therapeutic applications.

Career Highlights

Throughout his career, Nigel Sharfe has worked with HSC Research and Development Limited Partnership and HSC Research and Development Limited. His work in these organizations has allowed him to focus on innovative research and development in the biomedical field.

Collaborations

Sharfe has collaborated with esteemed colleagues such as Chaim M. Roifman and Thomas Grunberger, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Nigel Sharfe's contributions to the field of biomedical research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…